| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Reid Alexander Waldman is Chief Executive Officer at MANE. Reid Alexander Waldman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $22.8M at current prices.
The MANE filings lean toward selling, a net 67,500 shares.
Reid Alexander Waldman has 4 Form 4 filings on record from February 2026 to August 2026, across 2 companies: Chief Executive Officer at Veradermics (MANE), 2026; Director at Achieve Life Sciences (ACHV), 2026.
The 11 reported transactions were 5 open-market sales, 4 option or other derivative awards, 1 option exercise and 1 conversion.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $7.3M.
The only open-market sale was 67,500 shares of MANE at an average $107.86 on August 17, 2026, about $7.3M.